Maravai LifeSciences Sees FY23 EPS $(0.01)-$0.01 Vs $0.06 Est.; Revenue $275M-$285M Vs $308.73M Est.
Portfolio Pulse from Benzinga Newsdesk
Maravai LifeSciences has updated its financial guidance for FY23, projecting total revenue to be in the range of $275.0 million to $285.0 million, lower than the estimated $308.73 million. The company's adjusted EBITDA is expected to be between $55.0 million and $60.0 million, and its adjusted fully diluted EPS is expected to be between $(0.01) and $0.01 per share, lower than the estimated $0.06. The guidance does not include potential new acquisitions or unidentified items and is subject to risks and uncertainties.
November 08, 2023 | 12:40 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Maravai LifeSciences has lowered its FY23 revenue and EPS guidance, which could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
The company's lowered guidance for FY23, particularly the projected decrease in revenue and EPS, could be seen as a negative signal by investors, potentially leading to selling pressure and a decrease in the stock price. However, the impact could be mitigated if the market had already anticipated this adjustment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100